Congratulations to ABK Biomedical, winner of BioNova's first BioInnovation Challenge
September 29, 2011
McInnes Cooper congratulates ABK Biomedical, the winner of BioNova’s first BioInnovation Challenge.
“We are looking forward to working with ABK Biomedical. It’s exciting and important work with the potential to have a significant impact on the health of women,” says Robert Cowan, Partner at McInnes Cooper. The firm was a proud sponsor of the inaugural event, and donated a legal consultation to the winner.
Dr. Daniel Boyd, Dr. Robert Abraham, and their team at ABK Biomedical developed a new technology using OccluRad particles in the treatment of fibroid tumours. BioNova and the panel of judges for the challenge recognized this technology for its strong commercialization potential.
“We are thrilled to be able to support ABK’s creativity, innovation, and commitment to growth in Atlantic Canada, further demonstrating our dedication to helping companies such as these reach their potential,” says Cowan.
McInnes Cooper has placed a focus on serving innovative and high growth companies that require the high quality services of a large law firm, but are worried about costs at early stages of development. McInnes Cooper’s “BIG Potential Program”, helps support these unique new enterprises by making it affordable.
For more on ABK Biomedical and the BioInnovation Challenge, click here.
For more information on McInnes Cooper’s BIG Potential Program, click here.
- Share with others